首页 | 本学科首页   官方微博 | 高级检索  
     

口腔鳞癌患者血清可溶性MHC-I 类链相关蛋白A 的检测及其临床病理意义
引用本文:Li C,Shi F,Yang D,Wang J,Jian X,Jiang C. 口腔鳞癌患者血清可溶性MHC-I 类链相关蛋白A 的检测及其临床病理意义[J]. 中南大学学报(医学版), 2012, 37(2): 168-172. DOI: 10.3969/j.issn.1672-7347.2012.02.010
作者姓名:Li C  Shi F  Yang D  Wang J  Jian X  Jiang C
作者单位:1. 中南大学 湘雅医院口腔颌面外科,长沙 410008;
2. 中南大学 湘雅医学院免疫学系, 长沙 410078
基金项目:国家自然科学基金(30772437);湖南省科技计划一般项目(06sk3026,06sk3044)。
摘    要:目的:探讨口腔鳞癌患者血清中可溶性MHC-I 类链相关蛋白A (soluble major histocompatibility complex classI-related chain A,sMICA) 的表达水平及其临床意义。方法:选用口腔鳞癌患者78 例作为实验组,19 例健康成年人作为正常对照组,应用酶联免疫吸附定量分析法检测实验组和正常对照组血清中sMICA 的含量。结果:实验组血清sMICA 检出率为98.7%(77/78),其含量的95%可信区间为74.30~93.95 pg/mL,中位数为82.17 pg/mL;对照组血清sMICA 检出率为94.7%(18/19),其含量的95%可信区间为29.48~50.30 pg/mL,中位数为37.54 pg/mL,实验组血清sMICA 含量显著高于对照组(P<0.01)。实验组血清sMICA 含量在不同肿瘤大小、临床分期及颈部淋巴结是否转移与正常对照组比较,差异具有统计学意义(P<0.05);而不同性别、年龄及肿瘤分化程度两组间比较,差异无统计学意义(P>0.05)。结论:口腔鳞癌患者血清sMICA 表达水平增高,且与肿瘤大小、临床分期及颈部淋巴结转移相关,检测血清sMICA 的含量有助于判断口腔鳞癌患者的免疫功能状态。

关 键 词:口腔  鳞状细胞癌  MHC-I 类链相关蛋白A  免疫逃逸  
收稿时间:2011-01-26

Soluble major histocompatibility complex class I-related chain A in sera of patients with oral squamous cell carcinoma
Li Chao,Shi Fangqiong,Yang Dan,Wang Jie,Jian Xinchun,Jiang Canhua. Soluble major histocompatibility complex class I-related chain A in sera of patients with oral squamous cell carcinoma[J]. Journal of Central South University. Medical sciences, 2012, 37(2): 168-172. DOI: 10.3969/j.issn.1672-7347.2012.02.010
Authors:Li Chao  Shi Fangqiong  Yang Dan  Wang Jie  Jian Xinchun  Jiang Canhua
Affiliation:1. Department of Oral and Maxillofacial Surgery, Xiangya Hospital, Central South University, Changsha 410008;
2. Department of Immunology, Xiangya School of Medicine, Central South University, Changsha 410078, China
Abstract:Objective: To examine the expression of soluble major histocompatibility complex class I-related chain A (sMICA) in the serum in patients with oral squamous cell carcinoma (OSCC) and to explore its clinicopathological significance. Methods: Seventy-eight OSCC patients were selected as an experiment group, and 19 healthy persons as a control group. The sMICA in the serum in the experiment group and the control group was detected by enzyme-linked immunosorbent assay. Results: The detection rate of sMICA in the serum in the experiment group was 98.7% (77/78), with the 95% confidence interval 74.30-93.95 pg/mL and the median 82.17 pg/mL, The detection rate in the control group was 94.7% (18/19), with the 95% confidence interval 29.48-50.30 pg/mL and the median 37.54 pg/mL. The sMICA in the serum in the experiment group was higher than that in the control group (P<0.01). There was statistic difference in the serum sMICA in the experiment group among the different clinicopathological parameters such as tumor size, disease stage and regional lymph node status (P<0.05), but no difference was found in gender, age, and tumor differentiation (P>0.05). Conclusion: The sMICA in the serum in the OSCC patients increases, and is related with the tumor size, disease stage and regional lymph node status. Determination of sMICA in the serum may provide useful information to evaluate the immune state of OSCC patients.
Keywords:oral  squamous cell carcinoma  major histocompatibility complex class I-related chain A  immune escape
本文献已被 PubMed 等数据库收录!
点击此处可从《中南大学学报(医学版)》浏览原始摘要信息
点击此处可从《中南大学学报(医学版)》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号